{"product_id":"harrowinc-business-model-canvas","title":"Harrow Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a concise Business Model Canvas: clear value, scalable revenue, market advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Harrow’s strategic blueprint with our concise Business Model Canvas—three to five clear sentences showing how the company creates value, scales revenue, and secures market advantage. Dive deeper with the full, editable canvas (Word\/Excel) for section-by-section insights, financial implications, and ready-to-use templates—perfect for investors, consultants, and founders ready to act.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI and formulation suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReliable API and excipient suppliers ensure consistent quality and supply security; the global API market was valued at about USD 179 billion in 2024, underscoring supplier importance. Long-term agreements reduce cost and lead-time variability and stabilize COGS. Technical collaboration drives formulation optimization and faster tech transfer. Dual sourcing mitigates shortage risk and preserves production continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers (CMOs\/CDMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract manufacturers (CMOs\/CDMOs) supply sterile ophthalmic manufacturing, filling and packaging in ISO 5\/Grade A suites, meeting cGMP under 21 CFR parts 210 and 211. Sterility assurance targets SAL 10^-6 and robust quality systems are mandatory. Technology transfer and validation typically require 6–12 months to sustain scale-up. Flexible CMO capacity enables launches and rapid response to demand surges.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and acquisition partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOriginators and developers provide assets for in-licensing or acquisition, enabling Harrow to access late-stage branded and generic ophthalmics. Partnerships accelerate portfolio expansion across branded and generic products, targeting a U.S. ophthalmic Rx market of roughly $15B and indications like dry eye (≈16M), AMD (≈2.1M) and glaucoma (≈3M). Deal structures commonly balance upfronts ($1M–$50M), milestone pools ($5M–$200M) and royalties (5–25%), aligning risk and return to unmet U.S. eye care needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical sites and KOLs in ophthalmology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInvestigators and key opinion leaders guide clinical design and evidence generation, shaping endpoints and comparator choices. Their endorsement supports adoption among specialists and payer engagement. Access to clinical sites and patient populations expedites enrollment; ClinicalTrials.gov lists over 1,000 active ophthalmology studies in 2024. Ongoing KOL feedback informs lifecycle management and labeling strategies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRole: design, endpoints, evidence\u003c\/li\u003e\n\u003cli\u003eAdoption: specialist endorsement\u003c\/li\u003e\n\u003cli\u003eAccess: speeds enrollment (1,000+ studies, 2024)\u003c\/li\u003e\n\u003cli\u003eFeedback: lifecycle and label\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors, wholesalers, and GPOs\/PBMs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChannel partners enable national coverage across clinics, hospitals, and pharmacies; AmerisourceBergen, Cardinal Health, and McKesson together handle over 90% of US drug distribution.\u003c\/p\u003e\n\u003cp\u003eLeading PBMs—CVS Caremark, Optum Rx, and Cigna's Evernorth—manage roughly 80% of prescription claims and drive formulary access and pricing; data-sharing with distributors and GPOs improves demand planning, while contracting that aligns incentives supports volume and adherence.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNational reach via three major distributors \u0026gt;90%\u003c\/li\u003e\n\u003cli\u003eTop PBMs cover ~80% of claims\u003c\/li\u003e\n\u003cli\u003eGPO contracts yield double-digit savings\u003c\/li\u003e\n\u003cli\u003eData-sharing enhances demand planning and adherence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers, CMOs \u0026amp; PBMs: secure supply, speed launches and nationwide formulary access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic suppliers, CMOs, originators, KOLs, distributors and PBMs secure supply, speed launches and drive access while aligning economics via deals and data-sharing. Dual sourcing, long-term contracts and technical alliances reduce risk and COGS variability. Commercial partners (distributors\/PBMs) enable nationwide reach and formulary access.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI suppliers\u003c\/td\u003e\n\u003ctd\u003eSupply\/quality\u003c\/td\u003e\n\u003ctd\u003eMarket USD 179B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO\/CDMO\u003c\/td\u003e\n\u003ctd\u003eManufacturing\/sterile fill\u003c\/td\u003e\n\u003ctd\u003eTech transfer 6–12m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\/PBMs\u003c\/td\u003e\n\u003ctd\u003eDistribution\/formulary\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% \/ ~80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas for Harrow that details nine BMC blocks—customer segments, value propositions, channels, revenue streams, key resources, activities, partners, cost structure, and customer relationships—paired with SWOT-linked analysis and competitive insights to support presentations, funding, and strategic validation using real-company data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eStreamlines strategic planning by presenting a clean, editable one-page canvas that saves hours of formatting, clarifies core components for fast decision-making, and enables team collaboration for rapid iteration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct acquisition and licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eScouting and evaluating assets expanded Harrow's pipeline in 2024, screening over 100 candidates and closing multiple licensing deals to grow the portfolio efficiently. Diligence assessed clinical data, IP, CMC and market potential with typical spend above $1 million per asset. Negotiations used milestone-based risk-sharing to accelerate time-to-market, while integration plans targeted a 6–9 month commercialization acceleration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOptimizing ophthalmic formulations and delivery enhances outcomes and usability, reducing drop-out and improving adherence. Clinical trials generate safety and efficacy evidence; drug development typically spans about 10 years and costs roughly $1 billion. Real-world data increasingly supports differentiation and has informed regulatory decisions since the 2020 FDA RWE framework. Post-marketing studies refine positioning, labeling and market access strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory affairs and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePreparation and submission of NDAs\/ANDAs and supplements is core, with FDA review timelines in 2024 remaining 10 months for standard and 6 months for priority reviews. Ongoing communication with regulators keeps alignment on data and labeling. Robust pharmacovigilance and quality systems meet global reporting obligations. Label updates are issued promptly to reflect new data and safety signals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing, quality, and supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eManaging CMOs with strict QA\/QC and release testing secures product integrity and regulatory compliance; EU FMD introduced mandatory serialization in 2019 and the US DSCSA reached unit-level traceability milestones in 2023. Robust forecasting and inventory control minimize stockouts and optimize working capital. Serialization and validated cold-chain logistics ensure supply continuity for temperature‑sensitive products. Continuous improvement programs lower COGS and improve yield.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMO oversight + QA\/QC = product integrity\u003c\/li\u003e\n\u003cli\u003eEU FMD 2019; US DSCSA unit-level traceability 2023\u003c\/li\u003e\n\u003cli\u003eForecasting \u0026amp; inventory control prevent stockouts\u003c\/li\u003e\n\u003cli\u003eSerialization \u0026amp; cold-chain ensure compliance\u003c\/li\u003e\n\u003cli\u003eContinuous improvement reduces COGS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCommercialization and market access combine targeted field promotion that educates ophthalmologists and optometrists, payer contracting and rebate strategies to secure coverage and affordability, patient support programs to boost adherence, and digital and conference outreach to drive awareness; the global ophthalmic therapeutics market was estimated at about 38.5 billion USD in 2024, underscoring scale and opportunity.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField promotion: clinician education and KOL engagement\u003c\/li\u003e\n\u003cli\u003ePayer contracting: formulary access and rebates\u003c\/li\u003e\n\u003cli\u003ePatient support: adherence, copay assistance\u003c\/li\u003e\n\u003cli\u003eOutreach: digital campaigns and conference presence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaled asset scouting: 100+ candidates, \u0026gt;$1M diligence\/asset, targeting $38.5B ophthalmics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHarrow scaled asset scouting in 2024, screening 100+ candidates and closing multiple licenses with typical diligence spend \u0026gt;$1M per asset. Drug development timelines ~10 years and ~$1B; FDA reviews 10m standard\/6m priority (2024). Supply-chain controls (serialization, cold‑chain) and commercialization efforts target the $38.5B ophthalmics market (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKPI\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssets screened\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiligence cost\/asset\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e$38.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Harrow Business Model Canvas you’re previewing is the actual deliverable, not a mockup or sample. When you purchase, you’ll receive this exact, fully formatted file—complete and editable—in Word and Excel. No hidden pages, no filler content. What you see is what you’ll download and use immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162323267961,"sku":"harrowinc-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/harrowinc-business-model-canvas.png?v=1762698938","url":"https:\/\/portersfiveforce.com\/products\/harrowinc-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}